Navigation Links
BYDUREON™ RECEIVES MARKETING AUTHORIZATION IN EUROPE
Date:6/21/2011

ubmission builds upon six years of market experience with BYETTA® (exenatide) injection, the twice-daily form of exenatide that is available in more than 70 countries worldwide. The most common side effect with BYDUREON in clinical trials was mild-to-moderate nausea, which affected approximately 20 percent of patients and decreased over time in most patients. Other common side effects were vomiting, diarrhea and constipation.

In the U.S., the New Drug Application for BYDUREON (exenatide extended-release for injectable suspension) was submitted to the U.S. Food and Drug Administration (FDA) in 2009. The FDA issued a complete response letter and requested further data in late 2010. The companies plan to submit a response in the second half of 2011. BYDUREON is the proposed trade name.

BYDUREON is delivered using a biodegradable microsphere technology developed by Alkermes. The medicine offers a continuous release of exenatide with just one weekly dose.  

About Diabetes

Diabetes affects an estimated 285 million adults worldwide and nearly 26 million people in the U.S.(1),(2)  Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs exceed $174 billion per year in direct and indirect medical expenses.(3)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(4) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(5) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(6),(7)

About BYETTA® (exenatide) injection

BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETT
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BYDUREON™ Recommended for Approval in Europe
2. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
3. BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010
4. Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
5. Omnicells OmniRx Automated Medication Dispensing System Receives 2011 Best in KLAS Award
6. EndoSphere Inc. Receives Patent for Obesity Treatment
7. Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease
8. TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval
9. Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients
10. Mindray Medical Receives the 2011 Medical Device Excellence Award for its V Series Patient Monitoring System
11. MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... BOSTON , May 20, 2013  Rhythm announced ... study demonstrating a higher prevalence of gastroparesis symptoms among ... of these symptoms is high among patients with both ... is significantly under-diagnosed among those with the more common ... Kaplan , MD, PhD, Associate Professor of Medicine ...
(Date:5/20/2013)... , May 20, 2013  AbbVie (NYSE: ... a Phase 3 clinical study called SONAR (Study ... effects of the investigational compound atrasentan - when added ... disease in patients with stage 2 to 4 ... SONAR is a large, multinational, double-blind, placebo-controlled clinical ...
(Date:5/19/2013)... 2013 Claret Medical, Inc. announced the publication of ... et al., Histopathology of Embolic Debris Captured ... in Circulation, May 7 th this research is the ... Rotterdam, the Netherlands and the pathology team of ... Pathology Institute, Gaithersburg, Maryland.  This is the ...
Breaking Medicine Technology:Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2
... Spirogen Limited (the "Company") and Celtic Therapeutics Holdings ... Phase II clinical trial of SG2000 in ovarian cancer. ... Institute (NCI) of the USA, and is now actively ... II study will evaluate the overall response rate of ...
... Sept. 15 AstraZeneca (NYSE: AZN ... Drug Administration (FDA) has extended the time to ... (NDA) for ticagrelor (BRILINTA). (Logo: ... the FDA extended the Prescription Drug User Fee ...
Cached Medicine Technology:Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 2Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 3U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application 2
(Date:5/20/2013)... This summer, digital health leaders from across ... pilgrimage to San Diego, CA, the emerging digital health ... Summit produced by Living in Digital Times. ... the latest digital health innovations, exchange new information, share ... of industry’s most brilliant thinkers and doers, while elevating ...
(Date:5/20/2013)... By Dennis Thompson HealthDay Reporter , , MONDAY, ... with attention deficit-hyperactivity disorder (ADHD) are twice as likely ... the disorder when they were young, a new 30-year ... ADHD tended to have a higher body-mass index (BMI) ... of the disorder. Socioeconomics made no difference; well-off ...
(Date:5/20/2013)... subdural hematoma (PFSDH) is a serious and rare condition ... appropriate treatment, there,s an excellent chance of good long-term ... study in the May issue of Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , The results support an ...
(Date:5/20/2013)... Philadelphia, PA (May 21, 2013) Wolters ... its Lippincott Williams & Wilkins (LWW) published journals ... annual awards competition recognizes member articles and publications ... , "It,s a tremendous honor to be recognized ... have become synonymous in the industry with quality, ...
(Date:5/20/2013)... Today, Allayo announced the debut of their ... application called Allie helps health care consumers who are ... arrange for quality health care. Ideal for busy individuals ... technology and access to personalized service from certified medical ... care needs are being met. Allie is being previewed ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2
... application remains elusive, expert says , , WEDNESDAY, Feb. 25 ... of scientists has created two chemical compounds that appear ... a lack of oxygen. , "It is known that ... brain, which can be produced during hypoxia, it leads ...
... Chairman; Siegrist Takes on Executive PostSOUTH BEND, Ind., Feb. 25 ... transition from president and chief executive officer to chairman of ... Rick Siegrist, M.B.A., president of a Press Ganey subsidiary, PatientFlow ... Ganey Board of Directors, will take on the top executive ...
... White House to ,Protect the Safety Net, , WASHINGTON, ... two leading long-term care advocacy organizations, the American Health ... Home Care, today praised and thanked U.S. Representatives Earl ... and Ginny Brown-Waite (R-FL) for sending a new letter ...
... Laboratories(TM), a division of Ben Venue Laboratories, Inc., today ... product is AP rated and is equivalent to Imitrex(R) ... indicated for 1) the acute treatment of migraine attacks ... of cluster headache episodes. Sumatriptan Succinate Injection is not ...
... NEW YORK, February 25, 2009 The National ... awarded The City College of New York (CCNY) ... million grant to implement a unique partnership in ... award is funded by NCI,s U54 program, an ...
... COLORADO SPRINGS, Colo., Feb. 25 /PRNewswire/ -- ... the National Academy of Sciences, (NAS) report. Recognizing ... NAS report provides insight toward the path forward. ... improve and enhance the forensic sciences have been propounded, ...
Cached Medicine News:Health News:Compounds Found to Protect Rabbits From Cerebral Palsy 2Health News:Changing of the Guard at Press Ganey 2Health News:Changing of the Guard at Press Ganey 3Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 3Health News:Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection 2Health News:NIH awards $15.9 million to CCNY and Memorial Sloan-Kettering to create partnership 2
The Stat Profile pHOx CO-Oximeter is intended for use in those situations where a more comprehensive profile beyond the measured hematocrit, hemoglobin, and SO2% offered by the Stat Profile pHOx ...
Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Oximetry Data Management Program is a ... with the FingerPrint® Sleep Hand-Held Pulse ... PM, Inc. catalog #3389 Interface Cable, ... sleep screening, oxygen therapy validation, and/or ...
Medicine Products: